Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Obstructive Sleep Apnea. According to GlobalData, Phase I drugs for Obstructive Sleep Apnea have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Daridorexant hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Daridorexant hydrochloride overview

Daridorexant Hydrochloride (Quviviq) is a sleep-inducing agent. It is formulated as film-coated tablets for the oral route of administration. Quviviq is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Quviviq is indicated for the treatment of adult patients with insomnia characterized by symptoms present for at least 3 months and considerable impact on daytime functioning.

Idorsia Pharmaceutical overview

Idorsia Pharmaceutical (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia; aprocitentan for the treatment of resistant hypertension; clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage; and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder, and rare lysosomal storage disorders. It works in collaboration with Janssen Biotech to develop and commercialize Aprocitentan drug candidates. Idorsia is headquartered in Allschwil, Switzerland.

For a complete picture of Daridorexant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.